Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Efstathios Stathopoulos

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2009
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimenChara Papadaki, Dimitris Mavroudis, Maria Trypaki, et al.
Clinical Biochemistry|August 19, 2006
HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridizationMaria Ntoulia, Loukas Kaklamanis, Christos Valavanis, et al.
Clinical Chemistry and Laboratory Medicine|November 24, 2004
Bone marrow microvascular density and angiogenic growth factors in multiple myelomaMichael G Alexandrakis, Freda J Passam, Emmanuel Ganotakis, et al.
Plos One|September 24, 2013
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposideNiki Karachaliou, Chara Papadaki, Eleni Lagoudaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancerChara Papadaki, Maria Sfakianaki, Georgios Ioannidis, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 20, 2007
Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinomaKitty Pavlakis, Panteleimon Kountourakis, Efstathios Stathopoulos, et al.
Clinical Breast Cancer|February 14, 2008
Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancerMichail Ignatiadis, Maria Perraki, Stella Apostolaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancerMichail Ignatiadis, Galatea Kallergi, Maria Ntoulia, et al.
Plos One|December 25, 2013
BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcomeZacharenia Saridaki, Maria Tzardi, Maria Sfakianaki, et al.
Plos One|February 2, 2011
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patientsZacharenia Saridaki, Maria Tzardi, Chara Papadaki, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2009
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimenChara Papadaki, Dimitris Mavroudis, Maria Trypaki, et al.
Clinical Biochemistry|August 19, 2006
HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridizationMaria Ntoulia, Loukas Kaklamanis, Christos Valavanis, et al.
Clinical Chemistry and Laboratory Medicine|November 24, 2004
Bone marrow microvascular density and angiogenic growth factors in multiple myelomaMichael G Alexandrakis, Freda J Passam, Emmanuel Ganotakis, et al.
Plos One|September 24, 2013
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposideNiki Karachaliou, Chara Papadaki, Eleni Lagoudaki, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancerChara Papadaki, Maria Sfakianaki, Georgios Ioannidis, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 20, 2007
Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinomaKitty Pavlakis, Panteleimon Kountourakis, Efstathios Stathopoulos, et al.
Clinical Breast Cancer|February 14, 2008
Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancerMichail Ignatiadis, Maria Perraki, Stella Apostolaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancerMichail Ignatiadis, Galatea Kallergi, Maria Ntoulia, et al.
Plos One|December 25, 2013
BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcomeZacharenia Saridaki, Maria Tzardi, Maria Sfakianaki, et al.
Plos One|February 2, 2011
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patientsZacharenia Saridaki, Maria Tzardi, Chara Papadaki, et al.
Pageof 4